

GENTICEL ADDED TO THE ENTERNEXT[®] PEA-PME 150 INDEX

GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today announces that GENTICEL's shares have been included in the new EnterNext[®] PEA-PME 150 Index.

This new index, EnterNext[®] PEA-PME 150, is composed of 150 French companies among the 80% most liquid SMEs eligible for share-plan investment. This index will enhance Genticel's visibility to investors who can benefit from France's PEA-PME program's fiscal advantages on share purchases of up to €75,000.

This new EnterNext[®]PEA-PME 150 Index was launched on 17 November 2014.

Upcoming events:

Genticel will take part in various investor events over the coming months:

Petercam Healthcare CEO Seminar - Brussels

November 27, 2014

JP Morgan Healthcare Conference - San Francisco

January 12 - 15, 2015

About Genticel

Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.

Genticel is developing ProCervix, a first therapeutic vaccine in Phase II clinical trials, designed to eliminate cervical cells infected with HPV 16 and/or HPV 18. The company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.

Genticel is based in Paris and Toulouse and was awarded the 2013 Innovation Prize by the 'Grands Prix de l'Economie'.

Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.

For more information, please visit www.genticel.com



CONTACT GENTICEL

Benedikt Timmerman
Chief Executive Officer
investors@genticel.com

INVESTOR CONTACT

Corinne Puissant
Tel.: +33 (0)1 53 67 36 57
cpuissant@actus.fr

PRESS CONTACT

Alexandra Prisa
Tel.: +33 (0)1 53 67 35 79
aprisa@actus.fr